mercaptopurine has been researched along with Urinary-Bladder-Neoplasms* in 3 studies
3 other study(ies) available for mercaptopurine and Urinary-Bladder-Neoplasms
| Article | Year |
|---|---|
Single agent blinatumumab as frontline therapy for an 85-year-old patient with B cell precursor acute lymphoblastic leukemia.
Topics: Aged, 80 and over; Antibodies, Bispecific; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Breast Neoplasms; Carcinoma, Transitional Cell; Cytarabine; Female; Humans; Lymphoma, B-Cell; Mercaptopurine; Methotrexate; Neoplasms, Second Primary; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Remission Induction; Salvage Therapy; Urinary Bladder Neoplasms; Vincristine | 2016 |
[Role of activated cellular c-Ha-ras-1 oncogene in the mutagenic effect of the plasmid pEJ6.6].
The role of the activated oncogene c-Ha-ras-1 from human bladder carcinoma integrated into the pEJ6.6 plasmid in the mutagenic effect of the plasmid was studied in Chinese hamster cells. The frequency of hypoxanthine-phosphoribosyltransferase defective (HPRT-) mutants after treatment with pEJ6.6 containing an active c-Ha-ras-1 exceeded that in control dishes treated with a derivative of pEJ6.6 plasmid with an inactivated oncogene. The inactivation was achieved by introducing a deletion into the coding region of the oncogene. The mutagenic effect was rather weak but statistically significant. Thus, the data obtained show that the mutagenic activity of pEJ6.6 plasmid is determined by its oncogene. The role of mutagenic effects of activated cellular oncogenes in malignant transformation is discussed. Topics: Animals; CHO Cells; Cricetinae; Gene Deletion; Gene Expression Regulation; Genes, ras; Humans; Mercaptopurine; Mutagenesis; Plasmids; Restriction Mapping; Selection, Genetic; Transfection; Urinary Bladder Neoplasms | 1992 |
[The plasmid pEJ6.6 carrying the activated c-Ha-ras-1 oncogene increases the mutation frequency in Chinese hamster cells].
The induction of gene mutations and chromosome aberrations by the plasmid pEJ6.6 carrying the activated c-Ha-ras-1 oncogene from human bladder carcinoma was studied in cultured Chinese hamster cells. Both an increase in the frequency of gene mutations to 6-mercaptopurine resistance and of chromosome aberrations was observed after pEJ6.6 treatment as compared to control series (pBR322). Thus the results of experiments carried out show that the pEJ6.6 plasmid possesses a mutagenic activity. Topics: Animals; Cell Line; Chromosome Aberrations; Cricetinae; Cricetulus; Drug Resistance; Gene Expression Regulation, Neoplastic; Genes, ras; Humans; Mercaptopurine; Mutation; Plasmids; Urinary Bladder Neoplasms | 1992 |